Galapagos and Genentech extend drug discovery deal

Published: 18-Aug-2011
Research & Development Finance

Agreement has now been extended three times since 2005


Galapagos’ service division Argenta has signed a £21.5m (US$35.5m; €23.4m) extension to its contract drug discovery agreement with Genentech.

Medicinal chemistry, in vitro biology and screening will be performed to discover new chemical entities against undisclosed drug targets chosen by Genentech.

This is the third extension since the firms started working together in December 2005.

The extended agreement also allows Genentech to continue placing projects directly with Galapagos' other service division, BioFocus, which will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services.

BioFocus has been working with Genentech since an amendment to the Argenta agreement was signed in September 2010.

  • Companies:
  • Galapagos NV
  • Genentech
See more

You may also like

Drug Delivery

Galapagos and NovAliX enter integrated drug discovery collaboration

Read more
The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology

Trending Articles

  1. BioPharmaSpec expands its biopharma discovery and preclinical capabilities with three new facilities The contract research organisation (CRO) has expanded its European presence with three facilities, which are catered for biopharmaceutical drug discovery and preclinical characterisation
  2. Efficient PFAS-free degassing of aqueous solutions New silicone-based degassing chamber eliminates the risk of PFAS contamination
  3. CDMO market trends and dynamics The rise of the embedded model
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  5. Transmission Raman Spectroscopy - access the webinar series today Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Drug Delivery

Galapagos and NovAliX enter integrated drug discovery collaboration

The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology
Research & Development

Scenic Biotech enters into genetic modifier collaboration with Genentech

Multi-year strategic collaboration in target discovery and therapeutic development based on Scenic Biotech’s disease modifying approach
Research & Development

Galapagos expands fibrosis portfolio

Fibrosis small molecule programme has been announced as the focus of a partnership between Galapagos and Evotec
Research & Development

Pharnext announces R&D agreement with Galapagos

The main goal of this agreement is to generate an additional pipeline of novel synergistic drug combinations in a broad set of indications
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Optimising scale-up with flow process technologies

Speed of synthesis is of the essence when medicinal chemists invent new molecules, reports Sarah Houlton
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

ADCs: a more effective, less harmful, targeted approach

Antibody-drug conjugates could hold the key to delivering highly potent anticancer drugs more accurately to the tumour site with less damage to healthy cells
Regulatory

Rheumatoid arthritis – sarilumab

Not all patients respond well to or tolerate TNF-alpha inhibitors, and an alternative strategy might be to treat with a drug against the interleukin-6 receptor alpha
Subscribe now